Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996487 · ClinicalTrials.gov registry record · Phase 4
Screening to Prophylax Against Clostridium Difficile Infection -
A Phase 4 study, sponsored by Corewell Health East.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,294
- Enrollment target
NCT02996487: Completed Phase 4 study, sponsored by Corewell Health East.
NCT02996487 is a Phase 4 study that has completed, run by Corewell Health East. The registered enrollment target is 1,294 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996487, a Phase 4 study, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,294 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.
Primary Outcome
Number of participants with CDI in this subgroup of patients as assessed by clinical presentation, polymerase chain reaction (PCR) testing of stool, and EIA test for production of toxins. Patients are considered to have CDI if they have a positive PCR test, a positive toxin enzyme immunoassay (EIA) test, and clinical symptoms compatible with CDI. This outcome is only applicable to the two randomized arms.
Interventions
- OTHER Placebo
- DRUG Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,294 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 4 |
What the finished NCT02996487 record still lists
NCT02996487 is an interventional study that assigns participants to a tested intervention. Its 1,294 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02996487 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02996487 about?
NCT02996487 is a clinical study titled "Screening to Prophylax Against Clostridium Difficile Infection -". The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.
What is the current status of trial NCT02996487?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,294 participants. The study started on 2016-12-19. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT02996487?
The interventions under investigation include: Placebo (OTHER), Vancomycin (DRUG).
Who is sponsoring clinical trial NCT02996487?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02996487's enrollment target sits among peer trials
1,294 60th of 2000 higher than 1,941 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI